Search research articles
Contact Us
Filters
Showing results (251-260 of 306) with videos related to
Page
of 31
Sort By:
Leukemia
|
October 15, 2015
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
A M Zeidan, M A Sekeres, G Garcia-Manero, et al.
Leukemia Research
|
September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Kelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Blood
|
April 18, 2018
Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes
Eric Padron, Markus C Ball, Jamie K Teer, et al.
Cancer Discovery
|
March 27, 2016
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia
Sara E Meyer, Tingting Qin, David E Muench, et al.
The Lancet. Oncology
|
February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
Leukemia Research
|
July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
B Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Cancer Research
|
October 15, 2009
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies
Ying Ye, Michael A McDevitt, Mingzhou Guo, et al.
British Journal of Haematology
|
June 13, 2002
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
B Douglas Smith, Richard J Jones, Shing M Lee, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Cancer Research Communications
|
October 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
Mamta Parikh, Nataliya V Uboha, Naoko Takebe, et al.
Page
of 31
Search research articles
Search
Showing results (251-260 of 306) with videos related to
Sort By:
Page
of 31
Leukemia
|
October 15, 2015
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
A M Zeidan, M A Sekeres, G Garcia-Manero, et al.
Leukemia Research
|
September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Kelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Blood
|
April 18, 2018
Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes
Eric Padron, Markus C Ball, Jamie K Teer, et al.
Cancer Discovery
|
March 27, 2016
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia
Sara E Meyer, Tingting Qin, David E Muench, et al.
The Lancet. Oncology
|
February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.
Leukemia Research
|
July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
B Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Cancer Research
|
October 15, 2009
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies
Ying Ye, Michael A McDevitt, Mingzhou Guo, et al.
British Journal of Haematology
|
June 13, 2002
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
B Douglas Smith, Richard J Jones, Shing M Lee, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Cancer Research Communications
|
October 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
Mamta Parikh, Nataliya V Uboha, Naoko Takebe, et al.
Page
of 31